Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Gains from Investment Securities (2016 - 2025)

Surgery Partners' Gains from Investment Securities history spans 11 years, with the latest figure at -$10.9 million for Q2 2025.

  • For Q2 2025, Gains from Investment Securities changed N/A year-over-year to -$10.9 million; the TTM value through Jun 2025 reached $14.2 million, changed N/A, while the annual FY2023 figure was $33.7 million, 1772.22% up from the prior year.
  • Gains from Investment Securities for Q2 2025 was -$10.9 million at Surgery Partners, down from $10.7 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $65.8 million in Q2 2022 and bottomed at -$54.2 million in Q3 2022.
  • The 5-year median for Gains from Investment Securities is $7.0 million (2024), against an average of $2.9 million.
  • The largest annual shift saw Gains from Investment Securities plummeted 5000.0% in 2022 before it skyrocketed 175.51% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at $200000.0 in 2021, then tumbled by 5000.0% to -$9.8 million in 2022, then surged by 175.51% to $7.4 million in 2023, then fell by 5.41% to $7.0 million in 2024, then tumbled by 255.71% to -$10.9 million in 2025.
  • Per Business Quant, the three most recent readings for SGRY's Gains from Investment Securities are -$10.9 million (Q2 2025), $10.7 million (Q1 2025), and $7.0 million (Q1 2024).